Agenus Inc. and Zydus Lifesciences Announce $141M Strategic Collaboration to Boost Cancer Immunotherapy Development

Reuters

06-03

Agenus Inc. and Zydus Lifesciences Announce $141M Strategic Collaboration to Boost Cancer Immunotherapy Development

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, has announced a strategic collaboration with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE) to advance the development of botensilimab and balstilimab (BOT/BAL). The agreement includes a $75 million upfront payment to Agenus for transferring manufacturing assets, with potential additional payments up to $50 million contingent on BOT/BAL production orders. Zydus will gain exclusive licensing rights for BOT/BAL in India and Sri Lanka and make a $16 million equity investment in Agenus. This partnership aims to accelerate BOT/BAL clinical development, expand global manufacturing capabilities, and improve patient access to oncology therapeutics. Agenus will leverage Zydus' facilities in Emeryville and Berkeley, CA, for manufacturing, positioning these as flagship U.S. sites for biologics contract manufacturing services.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250603011983) on June 03, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540277596"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540277596\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2540277596?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-03 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540277596","market":"us","top_or_hot":-1,"title":"Agenus Inc. and Zydus Lifesciences Announce $141M Strategic Collaboration to Boost Cancer Immunotherapy Development","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agenus Inc. and Zydus Lifesciences Announce $141M Strategic Collaboration to Boost Cancer Immunotherapy Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, has announced a strategic collaboration with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE) to advance the development of botensilimab and balstilimab (BOT/BAL). The agreement includes a $75 million upfront payment to Agenus for transferring manufacturing assets, with potential additional payments up to $50 million contingent on BOT/BAL production orders. Zydus will gain exclusive licensing rights for BOT/BAL in India and Sri Lanka and make a $16 million equity investment in Agenus. This partnership aims to accelerate BOT/BAL clinical development, expand global manufacturing capabilities, and improve patient access to oncology therapeutics. Agenus will leverage Zydus' facilities in Emeryville and Berkeley, CA, for manufacturing, positioning these as flagship U.S. sites for biologics contract manufacturing services.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250603011983) on June 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agenus Inc. and Zydus Lifesciences Announce $141M Strategic Collaboration to Boost Cancer Immunotherapy Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgenus Inc. and Zydus Lifesciences Announce $141M Strategic Collaboration to Boost Cancer Immunotherapy Development\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-03 19:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agenus Inc. and Zydus Lifesciences Announce $141M Strategic Collaboration to Boost Cancer Immunotherapy Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, has announced a strategic collaboration with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE) to advance the development of botensilimab and balstilimab (BOT/BAL). The agreement includes a $75 million upfront payment to Agenus for transferring manufacturing assets, with potential additional payments up to $50 million contingent on BOT/BAL production orders. Zydus will gain exclusive licensing rights for BOT/BAL in India and Sri Lanka and make a $16 million equity investment in Agenus. This partnership aims to accelerate BOT/BAL clinical development, expand global manufacturing capabilities, and improve patient access to oncology therapeutics. Agenus will leverage Zydus' facilities in Emeryville and Berkeley, CA, for manufacturing, positioning these as flagship U.S. sites for biologics contract manufacturing services.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250603011983) on June 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL1zrrq7:1","article_id":"2540277596","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540277596","pubTimestamp":1748948445,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Agenus Inc. , a leader in immuno-oncology innovation, has announced a strategic collaboration with Zydus Lifesciences Ltd.  to advance the development of botensilimab and balstilimab . The agreement includes a $75 million upfront payment to Agenus for transferring manufacturing assets, with potential additional payments up to $50 million contingent on BOT/BAL production orders. Zydus will gain exclusive licensing rights for BOT/BAL in India and Sri Lanka and make a $16 million equity investment in Agenus. This partnership aims to accelerate BOT/BAL clinical development, expand global manufacturing capabilities, and improve patient access to oncology therapeutics. Agenus will leverage Zydus' facilities in Emeryville and Berkeley, CA, for manufacturing, positioning these as flagship U.S. sites for biologics contract manufacturing services.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and ti","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Agenus Inc.和Zydus Lifesciences宣布开展1.41亿美元战略合作，促进癌症免疫疗法开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGEN":0.9},"content_text":"Agenus Inc. and Zydus Lifesciences Announce $141M Strategic Collaboration to Boost Cancer Immunotherapy Development\n    \n\n        Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, has announced a strategic collaboration with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE) to advance the development of botensilimab and balstilimab (BOT/BAL). The agreement includes a $75 million upfront payment to Agenus for transferring manufacturing assets, with potential additional payments up to $50 million contingent on BOT/BAL production orders. Zydus will gain exclusive licensing rights for BOT/BAL in India and Sri Lanka and make a $16 million equity investment in Agenus. This partnership aims to accelerate BOT/BAL clinical development, expand global manufacturing capabilities, and improve patient access to oncology therapeutics. Agenus will leverage Zydus' facilities in Emeryville and Berkeley, CA, for manufacturing, positioning these as flagship U.S. sites for biologics contract manufacturing services.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250603011983) on June 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}